Protein kinases as drug targets in trypanosomes and Leishmania
Protein kinases as drug targets in trypanosomes and Leishmania
复制标题
DOI：
10.1016/j.bbapap.2005.08.018
复制
发表时间：
2005-12-30
影响因子：
3.2
通讯作者：
Mottram, JC
中科院分区：
文献类型：
--
作者：
Naula, C;Parsons, M;Mottram, JC
蛋白激酶代表了许多人类和动物疾病的有希望的药物靶点。最近完成了三种人类感染性锥虫原生动物（大型利什曼原虫、布氏锥虫和克氏锥虫）的基因组测序，使得每种寄生虫的激酶组分别被定义为 179、156 和 171 个真核蛋白激酶，大约是人类补体的三分之一。分析表明，锥虫缺乏受体相关或胞质酪氨酸激酶家族的成员，但具有丰富的 STE 和 CMGC 家族蛋白激酶，可能参与调节其复杂生命周期中的细胞周期控制、分化和应激反应。在这篇综述中，我们研究了利用寄生虫和哺乳动物蛋白激酶之间的差异来开发新型抗寄生虫化疗剂的前景。 (c) 2005 Elsevier B.V. 保留所有权利。
Protein kinases represent promising drug targets for a number of human and animal diseases. The recent completion of the sequenced genomes of three human-infective trypanosomatid protozoa, Leishmania major, Trypanosoma brucei and Trypanosoma cruzi, has allowed the kinome for each parasite to be defined as 179, 156 and 171 eukaryotic protein kinases respectively, that is about one third of the human complement. The analysis revealed that the trypanosomatids lack members of the receptor-linked or cytosolic tyrosine kinase families, but have an abundance of STE and CMGC family protein kinases likely to be involved in regulating cell cycle control, differentiation and response to stress during their complex life-cycles. In this review, we examine the prospects for exploiting differences between parasite and mammalian protein kinases to develop novel anti-parasitic chemotherapeutic agents. (c) 2005 Elsevier B.V. All rights reserved.